National Agency For The Safety Of Medicine And Health Products

CERTIFICATE NUMBER: ***21MPP074HFR01***

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER [1, 2]

Part 1

Issued following an inspection in accordance with :

The competent authority of France confirms the following:
The manufacturer: ***NOVASEP PROCESS***
Site address: ***Site Eiffel, Boulevard de la Moselle, POMPEY, 54340, France***

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2021-10-22***, it is considered that it complies with:

- The principles of GMP for active substances [3] referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2.The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

---

[1] *The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.*

[2] *Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.*

[3] *These requirements fulfil the GMP recommendations of WHO.*

Manufacture of active substance. Names of substances subject to inspection:
RUXOLITINIB PHOSPHATE(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES Active Substance:RUXOLITINIB PHOSPHATE	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.3 Salt formation / Purification steps: Chromatography
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps: Evaporation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Clarifying remarks (for public users)

RUXOLITINIB PHOSPHATE: Limited to the enantiomeric separation of the intermediate INCB032306 // Signatory : Mrs Linda Gallais, head of starting materials inspection department --- The ANSM does not issue hard copies of good practices certificates

2022-01-06

Name and signature of the authorised person of the Competent Authority of France

---

Confidential
National Agency For The Safety Of Medicine And Health Products
Tel:***Confidential***
Fax:***Confidential***